Tag Archives: second-line treatment

Immune Checkpoint Inhibitors for Recurrent Mesothelioma: Early Adoption Gave Them Traction

immune checkpoint inhibitors for recurrent mesothelioma

A new report shows that doctors started using immune checkpoint inhibitors for recurrent mesothelioma at least two years before the practice was officially sanctioned. This early adoption gave ICIs traction to quickly become part of clinical practice.  Immune checkpoint inhibitors block mesothelioma’s built-in resistance to immune system attack. They are among the most promising approaches to combating this intractable cancer.  University of Pennsylvania researchers recently ran a retrospective study on immune checkpoint inhibitors for recurrent mesothelioma. The study looked at real-world mesothelioma patients at several different medical centers. The researchers found that, even though the National Comprehensive Cancer Network (NCCN) did not revise it’s guidelines to include immune checkpoint inhibitors as a second-line treatment until 2017, doctors were using them … Continue reading Immune Checkpoint Inhibitors for Recurrent Mesothelioma: Early Adoption Gave Them Traction »

Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival

second-line treatment with ramucirumab

New evidence suggests that second-line treatment with ramucirumab after first-line chemotherapy may lead to longer survival in people with pleural mesothelioma.  Researchers in Italy recently published results of a double-blind, placebo-controlled trial of the drug. Ramucirumab inhibits a protein mesothelioma tumors need to form new blood vessels.  The study included 161 pleural mesothelioma patients from across Italy. Researchers gave half of them second-line treatment with ramucirumab and another drug called gemcitabine. The other half had second-line treatment with gemcitabine alone.  Results showed the ramucirumab group lived more than six months longer than those who got only gemcitabine.  Few Options for Recurrent Mesothelioma Pleural mesothelioma is an aggressive cancer with few good treatment options. Most patients start with chemotherapy with Alimta. … Continue reading Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival »

Comparing Second-Line Therapies for Recurrent Mesothelioma

recurrent mesothelioma

University of Pennsylvania researchers have some hopeful news for people with recurrent mesothelioma after chemotherapy: Second-line immunotherapy might increase their odds of survival. Previous studies show that recurrent mesothelioma patients who had immunotherapy lived longer than those on placebo. But doctors were not sure how second-line immunotherapy compared to second-line chemotherapy in these patients. The new study showed a clear survival advantage for those who had immunotherapy.  Coping with Recurrent Mesothelioma Malignant pleural mesothelioma is a rare cancer with a grim prognosis. Most people who receive a mesothelioma diagnosis start treatment with chemotherapy. A combination of Alimta (pemetrexed) and a platinum drug is the most common first-line treatment.  But even the standard-of-care rarely keeps this virulent cancer at bay for … Continue reading Comparing Second-Line Therapies for Recurrent Mesothelioma »

Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study

maintenance therapy

Dutch researchers say administering maintenance therapy with gemcitabine after chemotherapy may help mesothelioma patients live longer than supportive care alone.  Gemcitabine is an antimetabolite sold under the brand name Gemzar. Oncologists use it to treat several other types of cancer. When cancer cells absorb gemcitabine, they can no longer divide into new cancer cells.  Most mesothelioma patients have chemotherapy as their first-line treatment. If they are healthy enough, they may also have mesothelioma surgery. A maintenance therapy is a treatment that follows the main treatment. It is an effort to maintain the effects of the treatment.  The new Dutch study shows gemcitabine may be a safe and effective choice for maintenance therapy. What Does Maintenance Therapy Mean? Right now, there … Continue reading Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study »

Second-Line Mesothelioma Treatment with Ramucirumab

second-line mesothelioma treatment

A combination of ramucirumab (CYRAMZA) and gemcitabine creates a promising second-line mesothelioma treatment. New research shows the combination nearly doubled survival in a group of patients whose tumors kept growing with standard therapy.  Italian researchers shared their findings at the virtual annual meeting of ASCO. ASCO is one of the largest gatherings of cancer doctors in the US. First-Line Mesothelioma Treatment Failure For most mesothelioma patients, chemotherapy with Alimta is the first-line treatment. This does keep the cancer in check for some patients. But after a while, mesothelioma tumors almost always come back. Chemotherapy only extends survival by about four months.  Doctors have tested many different approaches to second-line mesothelioma treatment.  Some of the therapies tested are: Additional rounds of … Continue reading Second-Line Mesothelioma Treatment with Ramucirumab »

Second-Line Treatment for Mesothelioma with Lurbinectedin

second-line treatment for mesothelioma

Swiss researchers may have finally found an effective second-line treatment for mesothelioma.  Scientists with the Swiss Group for Clinical Cancer Research presented their findings at the recent European Society for Medical Oncology conference in Barcelona.  Mesothelioma patients who fail after first-line therapy have few options. The new study focused on lurbinectedin, a drug that impacts cancer cells at the DNA level. Early studies suggest lurbinectedin might make a good second-line treatment for small cell lung cancer.  According to the Swiss team, more than half of patients in their study responded to lurbinectedin as a second-line treatment for mesothelioma.  In Search of a Second-Line Mesothelioma Treatment Malignant mesothelioma is notoriously difficult to diagnose and even harder to treat. It is usually … Continue reading Second-Line Treatment for Mesothelioma with Lurbinectedin »